AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06437353
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily.
Trial: NCT05950724
Drug: Etanercept Injection [Enbrel]
RxNorm normalized name: etanercept Injection [Enbrel]
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg subcutaneous injection
Trial: NCT05775471
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05942027
Drug: Co-Enzyme Q10
RxNorm normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
Trial: NCT05623345
Drug: Izokibep
RxNorm normalized name: Izokibep
DrugBank: Izokibep (DB19081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Trial: NCT05623345
Drug: Placebo to izokibep
DrugBank: Izokibep (DB19081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Trial: NCT06313008
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
Trial: NCT06313008
Drug: Vildagliptin 50 MG
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
Trial: NCT06245629
Drug: Bortezomib-bendamustine-melphalan
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
Trial: NCT06462547
Drug: INZ-701
RxNorm normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Trial: NCT06518564
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.
Trial: NCT06518564
Drug: M1774
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.
Trial: NCT05343013
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIven by PO
Trial: NCT04835506
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab
Trial: NCT06365970
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
Trial: NCT06365970
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
Trial: NCT06333561
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Trial: NCT06333561
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks
Trial: NCT06333561
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg intravenously every 3 weeks
Trial: NCT06333561
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks
Trial: NCT06333561
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks
Trial: NCT06178679
Drug: ST-100 (vezocolmitide)
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
Trial: NCT04880785
Drug: Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
RxNorm normalized name: dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet [Dovato]
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
Trial: NCT04784104
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Trial: NCT04784104
Drug: Prilocaine HCl 2% Injectable solution
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Trial: NCT04924179
Drug: Tislelizumab plus Fruquintinib and SBRT
RxNorm normalized name: Tislelizumab
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
Trial: NCT06274528
Drug: Lemborexant 10 mg
RxNorm normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Within FDA approved dose 10 mg; capsule; QD, 6 month duration
Trial: NCT06274528
Drug: Lemborexant 20mg
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg; capsule; QD; 6 month duration
Trial: NCT05637671
Drug: oxybutynin ER
RxNorm normalized name: Oxybutynin Chloride 5 MG Oral Tablet, Extended Release [OXYBUTYNIN ER]
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
Trial: NCT05637671
Drug: Paroxetine CR
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
Trial: NCT06447376
Drug: Siltuximab
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.
Trial: NCT06175702
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose 1.5 mg/m2 at days 1, 8, 15 and 22
Trial: NCT06175702
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg on days 1-2, 8-9,15-16 and 22-23
Trial: NCT06175702
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg per day from 1 to up to 5 years
Trial: NCT06175702
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
Trial: NCT06175702
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg per day from consolidation start up to 5 years
Trial: NCT06447376
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg
Trial: NCT06175702
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
Trial: NCT06544577
Drug: ELacestrant
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 345 mg/day once daily oral dosing
Trial: NCT04824365
Drug: Sodium Pyruvate
RxNorm normalized name: Sodium Pyruvate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
Trial: NCT05407324
Drug: Dazucorilant 300 mg
RxNorm normalized name: Dazucorilant
DrugBank: Dazucorilant (DB18025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
Trial: NCT05407324
Drug: Dazucorilant 150 mg
RxNorm normalized name: Dazucorilant
DrugBank: Dazucorilant (DB18025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
Trial: NCT04792515
Drug: Camrelizumab combined with SOX/ or apatinib
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing.
Trial: NCT05953376
Drug: Calcium Gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
Trial: NCT04043598
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Trial: NCT00501579
Drug: Difluprednate
RxNorm normalized name: Difluprednate
DrugBank: Difluprednate (DB06781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05093322
Drug: Surufatinib in combination with Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Surufatinib in combination with Gemcitabine
Trial: NCT05932862
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib administered orally twice daily.
Trial: NCT06335173
Drug: sabirnetug
RxNorm normalized name: Sabirnetug
DrugBank: Sabirnetug (DB19438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sabirnetug
Trial: NCT05468138
Drug: SOX
RxNorm normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Trial: NCT05468138
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
Trial: NCT06555419
Drug: Nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as specified in the treatment arm.
Trial: NCT06530030
Drug: efanesoctocog alfa
RxNorm normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
Trial: NCT05554848
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period
Trial: NCT05554848
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
Trial: NCT04599504
Drug: Lisdexamfetamine Dimesylate (Medication)
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication will be taken daily in pill form.
Trial: NCT00005110
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00005110
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04965051
Drug: insulin degludec/insulin aspart (IDegAsp)
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To evaluate the efficacy and safety of the IDegAsp in T1DM
Trial: NCT04965051
Drug: basal insulin plus pre-prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
Trial: NCT00002355
Drug: Fomivirsen sodium
RxNorm normalized name: Fomivirsen Sodium
DrugBank: Fomivirsen (DB06759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06144814
Drug: Hyaluronic acid vaginal gel
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: . Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
Trial: NCT04128774
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The case group receives dexamethasone based on the clinical indication.
Trial: NCT04303845
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 140 mg of erenumab via subcutaneous injection
Trial: NCT05995119
Drug: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
RxNorm normalized name: apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
Trial: NCT05667194
Drug: KH617
RxNorm normalized name: Ketamine hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KH617 is s freeze-dried powder injection
Trial: NCT04234360
Drug: 5 days of systemic corticotherapy (prednisone)
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
Trial: NCT06296212
Drug: Saline solution 0.9% of sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
Trial: NCT04934475
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
Trial: NCT06299839
Drug: PAS-004 Capsules
RxNorm normalized name: PAS
DrugBank: PAS-004 (DB18611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.
Trial: NCT06299839
Drug: PAS-004 Tablets
RxNorm normalized name: PAS
DrugBank: PAS-004 (DB18611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.
Trial: NCT06378125
Drug: controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Trial: NCT06378125
Drug: immediate-release nicotinic acid (SAD)
RxNorm normalized name: NICOTINIC ACID
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Trial: NCT06509334
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Omalizumab every 4 weeks for 12 weeks
Trial: NCT06674109
Drug: Empagliflozin 10 mg
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For the empagliflozin arm, participants will take 10 mg daily.
Trial: NCT05515809
Drug: parasternal block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery
Trial: NCT00002185
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05537090
Drug: BV100
RxNorm normalized name: Bempedoic Acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rifabutin for Infusion
Trial: NCT05537090
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Syrup for oral administration